IRIS - Res&Arch Institutional Research Information System - Research & Archive

MARTELLI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.856
EU - Europa 4.108
AS - Asia 3.458
SA - Sud America 637
AF - Africa 65
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 9
Totale 13.145
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.762
SG - Singapore 1.555
IT - Italia 1.035
IE - Irlanda 696
HK - Hong Kong 556
BR - Brasile 532
CN - Cina 509
SE - Svezia 484
UA - Ucraina 468
RU - Federazione Russa 396
VN - Vietnam 372
DE - Germania 301
FI - Finlandia 258
KR - Corea 201
GB - Regno Unito 120
FR - Francia 55
TR - Turchia 55
AR - Argentina 51
AT - Austria 48
CA - Canada 45
BD - Bangladesh 38
IN - India 35
MX - Messico 34
NL - Olanda 34
BE - Belgio 32
LU - Lussemburgo 31
PL - Polonia 31
CZ - Repubblica Ceca 29
ZA - Sudafrica 29
CH - Svizzera 25
ES - Italia 18
IQ - Iraq 18
JP - Giappone 18
CO - Colombia 16
EC - Ecuador 15
RO - Romania 13
LT - Lituania 12
UZ - Uzbekistan 12
ID - Indonesia 11
AE - Emirati Arabi Uniti 9
LB - Libano 9
EU - Europa 8
GR - Grecia 8
MA - Marocco 8
CL - Cile 7
IL - Israele 7
KE - Kenya 7
PK - Pakistan 7
AU - Australia 6
OM - Oman 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
VE - Venezuela 5
PY - Paraguay 4
CI - Costa d'Avorio 3
CR - Costa Rica 3
EG - Egitto 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NP - Nepal 3
PA - Panama 3
PE - Perù 3
PT - Portogallo 3
QA - Qatar 3
BH - Bahrain 2
BO - Bolivia 2
DZ - Algeria 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
LK - Sri Lanka 2
PH - Filippine 2
TN - Tunisia 2
UG - Uganda 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MT - Malta 1
MY - Malesia 1
MZ - Mozambico 1
Totale 13.132
Salva come PNG Salva come JPEG
Città #
Singapore 998
Chandler 757
Dublin 696
Hong Kong 556
Perugia 460
San Mateo 357
Ashburn 297
Boardman 282
Jacksonville 223
Santa Clara 223
Dong Ket 216
Seoul 200
Altamura 161
Medford 154
Princeton 150
Beijing 123
Wilmington 123
Lawrence 118
Moscow 117
Munich 117
Ann Arbor 109
Andover 108
Los Angeles 94
New York 84
Helsinki 79
Des Moines 66
Piscataway 64
Turku 59
Ho Chi Minh City 57
São Paulo 50
Saint Petersburg 41
Izmir 36
The Dalles 36
Brussels 32
Falls Church 32
Dallas 31
Dudelange 30
Rome 30
Brooklyn 29
Hanoi 28
Redmond 28
Norwalk 27
Milan 26
Pisa 26
Belo Horizonte 25
San Paolo di Civitate 25
Woodbridge 24
Orem 23
San Francisco 23
Johannesburg 22
Nuremberg 22
Houston 21
Rio de Janeiro 21
London 20
Frankfurt am Main 19
Shanghai 19
Denver 18
Redwood City 18
Tokyo 18
Vienna 18
Warsaw 17
Boston 16
Chicago 16
Phoenix 16
Stockholm 16
Poplar 15
Council Bluffs 14
Dhaka 14
Florence 14
Foligno 14
Mexico City 14
Montreal 14
Amsterdam 13
Chennai 13
Auburn Hills 12
Bologna 12
Falkenstein 12
Hefei 12
Haiphong 11
Brno 10
Bucharest 10
Dearborn 10
Olomouc 10
Atlanta 9
Charlotte 9
Collazzone 9
Guangzhou 9
Manchester 9
Baghdad 8
Brasília 8
Secaucus 8
Ankara 7
Changsha 7
Columbus 7
Guayaquil 7
New Delhi 7
San Diego 7
Seattle 7
Terni 7
Castiglione del Lago 6
Totale 8.302
Salva come PNG Salva come JPEG
Nome #
Class IA PI3Ks regulate subcellular and functional dynamics of IDO1 188
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 156
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 152
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 143
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 141
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. 136
Maesopsin 4-O-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN! and BCAS3 in acute myeloid leukemia 129
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 122
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) 121
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 116
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. 114
Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells. 114
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 114
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features 113
ARPIR: automatic RNA-Seq pipelines with interactive report 113
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 111
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 110
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. 108
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 105
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 104
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 104
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 103
Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to Sumo-1 in murine thymocytes 102
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 100
Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse 100
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 96
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 96
From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo [4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia 96
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 95
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 95
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. 94
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 94
Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission? 93
Exon-12 nucleophosmin (NPM) mutation and aberrant cytoplasmic expression of NPM protein in leukemia cell line OCI-AML3 93
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants 93
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 93
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 93
Acute Myeloid Leukemia with mutated nucleophosmin (NPM1). Any hope for a targeted therapy? 92
BRAF mutations in hairy-cell leukemia. 92
Pharmacological modulation of caspase-8 in thymus-related medical conditions. 92
Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia 92
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML) 91
Failure of gelsolin overexpression to regulate lymphocyte apoptosis. 90
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 90
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 90
EML4-ALK rearrangement in non-small-cell lung cancer and non-tumor lung tissues. 89
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. 89
Mutant NPM1 Maintains the Leukemic State through HOX Expression 89
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. 88
CD123 (IL-3R alpha) IS CONSISTENTLY EXPRESSED ON ACUTE MYELOID LEUKEMIA (AML) CARRYING NUCLEOPHOSMIN (NPM1) GENE MUTATION 87
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia 87
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. 86
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 86
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 85
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. 85
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 85
Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants 85
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor 84
Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. 84
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 84
Poor risk acute myelogenous leukemia patients undergoing the Fludarabine-Cytosine Arabinoside-Filgrastim regimen: multidrug resistance expression, granulocyte colony-stimulating factor priming activity and clinical response. 83
Cellular and Molecular Biology of Lymphoid Cell 83
Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. 83
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia 83
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. 82
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. 82
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 81
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 81
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia 81
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 81
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. 80
HLA-MATCHED TREG/TCON ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ENSURES REMARKABLE CHRONIC GVHD/LEUKEMIA FREE SURVIVAL IN HIGH-RISK LEUKEMIA PATIENTS 80
Stem cell mobilization in normal donors. 79
Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype 79
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 78
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice 78
MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. 77
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 77
Histone Deacetylase Inhibitors Induce Cell Growth Inhibition and Apoptosis in NPM1-Mutated AML Cells: A Possible Role for Epigenetic Therapies in AML Carrying NPM1 Gene Mutations 77
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by 67 Gallium scan in 50 patients. 76
NPM1-mutated AML: targeting by disassembling 76
ADDITION OF THIOTEPA IMPROVES RESULTS IN T-CELL DEPLETED BONE-MARROW TRANSPLANT FOR ADVANCED LEUKEMIA 76
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients 76
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 75
Current status and future perspectives in targeted therapy of NPM1-mutated AML 74
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 74
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells 74
ADOPTIVE IMMUNOTHERAPY WITH REGULATORY AND CONVENTIONAL T CELLS AFFORDS HIGH RATE OF CHRONIC GVHD/RELAPSE-FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION 74
Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. 74
Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. 74
IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. 74
SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED 3-LOCI MISMATCHED TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RHG-CSF-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM 74
BRAF V600E mutation in hairy cell leukemia: From bench to bedside 74
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 73
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma 73
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin 72
Fibrin-associated large B-cell lymphoma: first case report within a cerebral artery aneurysm and literature review 72
Actinomycin d targets npm1c-primed mitochondria to restore pml-driven senescence in aml therapy 71
Role of caspase-8 in thymus function 70
Overlapping features of therapy-related and de novoNPM1-mutated AML 69
Totale 9.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.937
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021753 0 0 0 0 0 95 67 39 154 57 96 245
2021/20221.536 39 290 23 79 61 23 17 381 30 130 236 227
2022/20232.467 164 457 24 198 199 287 5 108 897 35 68 25
2023/20241.055 53 112 66 20 10 7 247 12 83 48 195 202
2024/20252.974 109 248 162 134 360 131 169 240 534 161 476 250
2025/20263.007 441 390 279 766 879 252 0 0 0 0 0 0
Totale 13.690